Electronic Acknowledgement Receipt				
EFS ID:	1411178			
Application Number:	10510585			
International Application Number:				
Confirmation Number:	1893			
Title of Invention:	Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies			
First Named Inventor/Applicant Name:	Debra L. Fleenor			
Correspondence Address:	Alcon Research - 6201 South Freeway - Fort Worth TX 76134-2099 US -			
Filer:	Mark E. Flanigan/Sue Stockton			
Filer Authorized By:	Mark E. Flanigan			
Attorney Docket Number:	2354 US F			
Receipt Date:	02-JAN-2007			
Filing Date:	08-OCT-2004			
Time Stamp:	18:13:33			
Application Type:	U.S. National Stage under 35 USC 371			
Payment information:				
Submitted with Payment	no			

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)			
1		Amendment_Response_File d_010207.pdf	141771	yes	5			
	Multipart Description/PDF files in .zip description							
	Document Description		Start	End				
	Amendment - After Non-Final Rejection		1	1				
	Claims		2	3				
	Applicant Arguments/Remarks Made in an Amendment		4	5				
Warnings:								
Information:								
Total Files Size (in bytes); 141771								

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card. as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.